Atossa Therapeutics Announces $16.5 Million Offering to Advance Oncology Clinical Development

Atossa Therapeutics, Inc. has announced a registered direct offering aimed at raising up to $16.5 million in gross proceeds, which will primarily support its clinical development efforts in oncology. The offering, set to close on June 12, 2026, includes an upfront amount of $4.5 million and warrants that could generate an additional $12 million if exercised. The company sells 1,363,638 shares of its common stock at $0.18 each, along with Series A and Series B warrants. The Series A warrants have a longer shelf life, expiring after 5.5 years, while the Series B warrants will expire in two years. Rodman & Renshaw LLC serves as the exclusive placement agent for this offering, underscoring the company’s strategic moves to bolster its financial position for ongoing clinical projects.

Funding Focused on Oncology Advancement

Atossa Therapeutics plans to allocate the proceeds from this offering towards advancing its oncology product candidates, including its lead candidate, (Z)-endoxifen, which is currently in clinical development. This move is a clear indication of the company's commitment to addressing substantial unmet medical needs in oncology. The possibility of significant additional proceeds from warrant exercises could provide flexibility in funding and expediting clinical timelines.

Strategic Capital Raising Under 'Shelf' Registration

Furthermore, the offering is filed under a 'shelf' registration statement effective since May 23, 2024, which facilitates future capital-raising efforts efficiently. Alongside this, Atossa includes forward-looking statements regarding the completion of the offering, emphasizing that actual outcomes might deviate based on market conditions. This strategic fundraising initiative positions Atossa Therapeutics to reinforce its pipeline and operational capacities, reflecting a calculated approach to maintaining momentum in the competitive oncology sector.

Conclusion

In summary, the recent offering by Atossa Therapeutics represents a pivotal step in securing funds aimed at enhancing its oncology initiatives, showcasing a proactive strategy to navigate funding challenges in the biotech landscape.